SciCombinator

Discover the most talked about and latest scientific content & concepts.

Estimation of clinical trial success rates and related parameters

OPEN Biostatistics (Oxford, England) | 3 Feb 2018

CH Wong, KW Siah and AW Lo
Abstract
Previous estimates of drug development success rates rely on relatively small samples from databases curated by the pharmaceutical industry and are subject to potential selection biases. Using a sample of 406 038 entries of clinical trial data for over 21 143 compounds from January 1, 2000 to October 31, 2015, we estimate aggregate clinical trial success rates and durations. We also compute disaggregated estimates across several trial features including disease type, clinical phase, industry or academic sponsor, biomarker presence, lead indication status, and time. In several cases, our results differ significantly in detail from widely cited statistics. For example, oncology has a 3.4% success rate in our sample vs. 5.1% in prior studies. However, after declining to 1.7% in 2012, this rate has improved to 2.5% and 8.3% in 2014 and 2015, respectively. In addition, trials that use biomarkers in patient-selection have higher overall success probabilities than trials without biomarkers.
Tweets*
359
Facebook likes*
1
Reddit*
0
News coverage*
133
Blogs*
6
SC clicks
0
Concepts
Estimator, Statistics, ClinicalTrials.gov, Drug development, Drug discovery, Pharmaceutical industry, Pharmacology, Clinical trial
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com